Updated:
Estrella Immunopharma
Cheng Liu's Estrella Immunopharma, a clinical-stage biotech, develops off-the-shelf allogeneic CAR-T therapies, listing on Nasdaq in 2023.
Estrella Immunopharma
Estrella Immunopharma was incorporated in 2021 and is headquartered in Berkeley, California. President and CEO Cheng Liu, a physician-scientist, leads the company's effort to move allogeneic CAR-T cell therapies toward regulatory approval. The firm listed on Nasdaq in January 2023 under the ticker ESLA. The company's sole disclosed pipeline asset is EB103, a CD19-targeted allogeneic CAR-T product candidate. The core structural bet is on donor-derived T cells, which the firm believes can be manufactured at scale and stored as an off-the-shelf treatment for B-cell malignancies, avoiding the costly, weeks-long personalization required by approved autologous CAR-T products such as Novartis's Kymriah or Gilead's Yescarta. Preclinical work evaluates dosing, persistence, and tumor-killing capacity against CD19-positive leukemia and lymphoma models. The geographic focus is the United States. As a pre-revenue biotechnology company, Estrella's resources are almost entirely dedicated to R&D. The organization is lean, with no secondary offices or adjacent vehicles disclosed. In January 2023, Estrella completed an initial public offering on the Nasdaq Capital Market, raising capital to fund the preclinical and potential early clinical development of EB103. Estrella's structural differentiator is its pursuit of an allogeneic, 'universal donor' CAR-T platform within a publicly traded micro-cap structure. Most allogeneic CAR-T development remains inside private companies or large pharmaceutical pipelines. A public listing at this preclinical stage creates a transparent window into the hit-or-miss nature of early platform validation, distinct from the pre-IPO venture-backed model that dominates the cell therapy space.
General information
Firm type
Asset Manager
Year founded
2021
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Berkeley
Corporate office
Berkeley, CA, United States
Principals
Cheng Liu
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is Estrella Immunopharma's lead drug candidate?
Estrella's sole disclosed pipeline asset is EB103, a CD19-targeted allogeneic CAR-T cell therapy. The product candidate uses donor-derived T cells and is being evaluated preclinically for the treatment of B-cell malignancies, including leukemias and lymphomas. The company has not yet commenced human clinical trials.
How does Estrella's approach differ from approved CAR-T therapies?
Approved CAR-T products like Kymriah and Yescarta are autologous, meaning they are manufactured using a patient's own T cells in a bespoke, weeks-long process. Estrella is pursuing an allogeneic approach, using T cells from healthy donors to create an 'off-the-shelf' product. The company's thesis is that this model could reduce manufacturing time, lower cost, and eliminate the risk of manufacturing failure for heavily pre-treated patients.
Who runs investment and operational decisions at Estrella Immunopharma?
Cheng Liu serves as President and Chief Executive Officer, leading both the corporate strategy and the scientific direction of the company. As a physician-scientist, Liu is central to advancing the preclinical development of EB103. Public company filings do not identify a separate chief investment officer or external investment committee, which is typical for a preclinical-stage biotech where capital allocation is equivalent to R&D prioritization.
Is Estrella Immunopharma a family office or an operating company?
Estrella Immunopharma is a publicly traded clinical-stage biopharmaceutical company, not a family office. It is an operating company incorporated in Delaware and listed on the Nasdaq Capital Market under the ticker ESLA. The firm raises capital through public equity markets to fund research and development.
What stage of development is EB103 currently in?
EB103 is in the preclinical stage. Estrella's disclosures indicate that the company is conducting laboratory and animal model studies to assess the product candidate's safety, persistence, and efficacy against CD19-positive tumor cells. No Investigational New Drug (IND) application has been publicly announced, and human trials have not begun.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: